GgoogleCA first seen 2 h ago, last 13 min ago, peak #1
Singapore approves Wegovy for liver disease MASH
Original: fat
Novo Nordisk has received approval in Singapore for Wegovy as the first treatment for MASH, a liver disease involving fibrosis. It marks a new indication for the weight-loss drug beyond obesity and diabetes. Attention centres on how semaglutide could expand into treating fatty liver disease globally.
Why now: Novo Nordisk's drug is expanding into a major new disease area, extending the hype around GLP-1 treatments
Rank over time, top of the chart is #1. 9 snapshots from 2 h ago to 13 min ago.
Evidence
- Backpack voted Fat Bear Week 2026 winner, beating out another offspring of former champ · CBS News
- Meet This Year's Chonky Champion of Fat Bear Week: Backpack, a Laid-Back 20-Year-Old Male Who's a 'Stoic Presence on the River' · Smithsonian Magazine
- Novo receives Singapore approval for Wegovy® as first treatment for MASH with liver fibrosis · PR Newswire
API: https://socialmediatrends-api.osmike.com/v1/trends/631065